Company: ABUS
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012305
Chunk: 59

Company: Arbutus Biopharma Corp
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 59
---
 Act, which was enacted on December 22, 2017, eliminated the exemption from the $1.0 million deduction limitation for performance-based compensation. There were also amendments to address certain administrative matters as follows:

| (a) | To change all references from “Tekmira Pharmaceuticals Corporation” to “Arbutus Biopharma Corporation”; |

| (b) | To restrict, with limited exceptions, the Compensation Committee’s power, without prior Shareholder approval, to effect any re-pricing of any previously granted “underwater” options or tandem stock appreciation rights; |

| (c) | To clarify the treatment of certain awards subject to Section 409A of the Code; and |

| (d) | To make certain conforming amendments to the 2011 Plan to reflect the above. |

The above is a summary only and is qualified in its entirety by the full text of the 2011 Plan, as amended. At the 2016 Annual General and Special Meeting, our Shareholders approved the 2016 Plan, which has been subsequently amended and supplemented and currently provides for the issuance of 33,500,000 Common Shares. Since January 1996 and through March 24, 2025, the equivalent of 7,647,139 Common Shares have been issued pursuant to the exercise of options and the vesting of restricted stock units granted under our equity compensation plans (which represents approximately 4% of our issued and outstanding Common Shares), and as of March 24, 2025, there were 19,456,684 of our Common Shares subject to options and restricted stock units outstanding under our equity compensation plans (which represents approximately 10% of our current issued and outstanding Common Shares). The number of our Common Shares remaining available for future grants as of March 24, 2025 was 12,689,410 (which represents approximately 7% of our issued and outstanding Common Shares).

38

TABLE OF CONTENTS

Equity Compensation Plan Information The following table sets forth information regarding our equity compensation plans as of December 31, 2024:

| Plan category                                              |     |        Number of 
 securities to be 
      issued upon 
      exercise of 
      outstanding 
          options 
              (a) |     |    Weighted-average 
   exercise price of 
 outstanding options 
                 (b) |     |            Number of 
           securities 
  remaining available 
  for future issuance 
         under equity 
   compensation plans 
           (excluding 
 securities reflected